You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Histone deacetylase (HDAC) inhibitor (IC50 = 7.5 to 16 nM). At low concentrations reduces release of pro-inflammatory cytokines, including TNFα, INFγ, IL-1α and IL-1β, from LPS stimulated PBMCs in vitro. Exhibits anti-inflammatory effects in vivo. Improves functional recovery and attenuates tissue damage in a mouse model of traumatic brain injury.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 457.95. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.18 mL||10.92 mL||21.84 mL|
|5 mM||0.44 mL||2.18 mL||4.37 mL|
|10 mM||0.22 mL||1.09 mL||2.18 mL|
|50 mM||0.04 mL||0.22 mL||0.44 mL|
References are publications that support the biological activity of the product.
Leoni et al (2005) The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol.Med. 11 1 PMID: 16557334
Shein et al (2009) Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury. FASEB.J. 23 4266 PMID: 19723705
If you know of a relevant reference for Givinostat hydrochloride, please let us know.
View Related Products by Product Action
Keywords: Givinostat hydrochloride, Givinostat hydrochloride supplier, HDAC, histone, deacetylase, inhibitors, inhibits, ITF2357, Givinostat, anti-inflammatory, ITF, 2357, Non-selective, HDACs, Non-Selective, 6249, Tocris Bioscience
Citations for Givinostat hydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for Givinostat hydrochloride. Do you know of a great paper that uses Givinostat hydrochloride from Tocris? Please let us know.
Reviews for Givinostat hydrochloride
There are currently no reviews for this product. Be the first to review Givinostat hydrochloride and earn rewards!
Have you used Givinostat hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epigenetics Scientific Review
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
Epigenetics Research Bulletin
Produced by Tocris and updated in 2014, the epigenetics research bulletin gives an introduction into mechanisms of epigenetic regulation, and highlights key Tocris products for epigenetics targets including:
- DNA Methyltransferases
- Histone Deacetylases
- Histone Demethylases
- Histone Methyltransferases
Rheumatoid Arthritis Poster
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.